Medicare

Proposed rule would cut some low-income drug copays, tighten Medicare Advantage provider directory standards, and increase PBM oversight.

The pharma trade group claims CMS exceeded its authority with the Medicare Part B pricing model.

Centene Corporation joins a growing list of payors launching programs that exempt qualified providers from certain PA requirements.

New surveys show growing public backing for Medicare for All ahead of the 2026 midterms, though partisan divides and cost concerns remain.

AHA report says reimbursement gaps, workforce shortages, and policy changes are intensifying financial strain on rural hospitals.

CLIA looks to expand virtual access, update lab staffing rules, and modernize oversight as CMS and CDC review regulations.

AZ argues CMS exceeded authority under the Inflation Reduction Act by grouping separate medicines under a single drug definition.

HRSA identified 10 drugmakers and 21 drugs for its revised 340B rebate pilot, reviving debate over oversight, costs and provider access.